FMP
TransCode Therapeutics, Inc.
RNAZ
NASDAQ
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
0.458 USD
-0.004 (-0.873%)
Historical Prices
From:
To:
About
ceo
Mr. Thomas A. Fitzgerald M.B.A.
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or eliminati...
CIK
0001829635
ISIN
US89357L3033
CUSIP
89357L105
Address
6 Liberty Square
Phone
857-837-3099
Country
US
Employee
8
IPO Date
Jul 8, 2021
Financial Statement
Earnings
RNAZ Financial Summary
CIK
0001829635
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
89357L105
ISIN
US89357L3033
Country
US
Price
0.46
Beta
1.52
Volume Avg.
7.34M
Market Cap
10.69M
Shares
-
52-Week
0.38-66.33
DCF
12.94
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-
P/B
-
Website
https://www.transcodetherapeutics.com
Upgrades and Downgrades
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest RNAZ News
InvestorPlace
May 13, 2024
Why Is TransCode Therapeutics (RNAZ) Stock Down 14% Today?
TransCode Therapeutics (NASDAQ: RNAZ ) stock is sliding lower on Monday following its announcement of an upcoming annual shareholder meeting. TransCode Therapeutics has informed investors in RNAZ stock that the company will hold its annual shareholder meeting on June 13, 2024 at 9:30 a.m Eastern Time.
GlobeNewsWire
Mar 6, 2024
TransCode Therapeutics To Present At 2024 RNA Leaders Europe...
BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that its Chief Scientific Officer, Zdravka Medarova, Ph.D., will present at this year's RNA Leaders Europe Congress scheduled to take place March 12-14 in Basel, Switzerland.
Zacks Investment Research
Jan 19, 2024
TransCode (RNAZ) Down 50% on Issue of New Common Stock
TransCode Therapeutics (RNAZ) will issue secondary shares and warrants, diluting its current shareholder base. The company plans to raise $7.5 million in gross proceeds from this issue.
InvestorPlace
Oct 27, 2023
Why Is TransCode Therapeutics (RNAZ) Stock Down 25% Today?
TransCode Therapeutics (NASDAQ: RNAZ ) stock is taking a beating on Friday after the oncology company announced plans for a public share offering. TransCode Therapeutics hasn't yet revealed details of the proposed public stock offering.
InvestorPlace
Sep 26, 2023
Why Is TransCode Therapeutics (RNAZ) Stock Down 69% Today?
TransCode Therapeutics (NASDAQ: RNAZ ) stock is falling hard on Tuesday after the medical company announced a public share offering. According to a press release, TransCode Therapeutics is offering 15.7 million shares of RNAZ stock for 51 cents each.
Proactive Investors
Sep 26, 2023
Transcode Therapeutic stock whipsaws lower after cut price p...
TransCode Therapeutics (NASDAQ:RNAZ) stock has seen a wild 24 hours of trading as the Boston headquartered nano-cap drug discovery firm rocketed Monday, before coming back down to earth with an after-hours equity raise. On the back of preclinical results the RNA oncology stock traded as high as $3.20 and closed at $2.55, from a starting price of 66 cents.
InvestorPlace
Sep 25, 2023
Why Is TransCode Therapeutics (RNAZ) Stock Up 240% Today?
Enlivening a soft Monday session on Wall Street, TransCode Therapeutics (NASDAQ: RNAZ ) saw its shares drive up 300% earlier this morning before settling around 240% up in the early afternoon session. Catapulting sentiment was news that TransCode's lead therapeutic candidate, TTX-MC138, demonstrated encouraging pre-clinical results.
Proactive Investors
Sep 25, 2023
TransCode Therapeutics stock skyrockets on positive brain ca...
TransCode Therapeutics (NASDAQ:RNAZ) shares took off after it announced positive results from a study of its lead drug candidate TTX-MC138 in mice models bearing human glioblastoma multiforme (GBM) tumors. Shares of the Boston-based RNA oncology company added 30.8.1% to US$2.71 in early trade on Monday.
